Teva’s Decline Fleeting to Bernstein Amid Board Fix

Teva Pharmaceutical Industries Ltd. is set to rebound from the biggest weekly slump since November as a pledge to overhaul the Israeli company’s board offsets earnings growth concerns, Sanford C Bernstein & Co. said.

While American depositary receipts of Teva, the world’s biggest maker of generic drugs, declined 3 percent last week, the shares are still up 7.1 percent this year. The Bloomberg Israel-US Equity Index of the largest Israeli companies traded in New York retreated 3.1 percent last week